{"filings":[{"id":91453,"accession_number":"0001127703-26-000018","cik":1127703,"company_name":"PROASSURANCE CORP","ticker":"PRA","form_type":"8-K","filed_at":"2026-05-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"ProAssurance Q1 operating income $12.7M; merger with Doctors Company targets June 30 close","event_type":"earnings","confidence":"high","bullets":["Net income $8.5M ($0.16 diluted EPS); operating income $12.7M ($0.25 diluted EPS).","Consolidated net premiums written $258.6M; Specialty P&C renewal premium increases 6% (cumulative >80% since 2018).","Non-GAAP combined ratio improved 2.3 points to 109.9%; expense ratio improved 0.3 points.","Merger with The Doctors Company awaits regulatory approvals in CA and PA; target close by June 30, 2026.","Book value per share $25.94, down $0.30 from year-end; adjusted book value $27.86."],"consensus_eps_estimate":null,"consensus_eps_actual":0.16,"consensus_revenue_estimate":null,"consensus_revenue_actual":262634000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":101536,"accession_number":"0001127703-26-000006","cik":1127703,"company_name":"PROASSURANCE CORP","ticker":"PRA","form_type":"8-K","filed_at":"2026-02-23T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"ProAssurance reports Q4 net income $33.4M ($0.64 EPS); merger update","event_type":"earnings","confidence":"high","bullets":["Q4 net income $33.4M ($0.64 diluted EPS); operating income $42.4M ($0.82 diluted EPS).","Full-year net premiums written $916.9M; Specialty P&C renewal premiums up 8% in 2025.","Consolidated Non-GAAP combined ratio improved 4.8 pts to 104.2% for 2025; Specialty P&C 98.3%.","Book value per share $26.24 at Dec 31 2025, up $2.75 from year-end 2024.","Pending merger with Doctors Company; approvals in 6 states, pending in CA and PA; close expected by June 30, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":0.99,"consensus_revenue_estimate":null,"consensus_revenue_actual":1098028000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":117880,"accession_number":"0001127703-25-000015","cik":1127703,"company_name":"PROASSURANCE CORP","ticker":"PRA","form_type":"8-K","filed_at":"2025-12-08T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"ProAssurance approves early bonus payouts to NEOs to mitigate Section 280G impact","event_type":"other_material","confidence":"high","bullets":["Compensation Committee approved early payments of ~80% of 2025 annual cash incentive awards to NEOs.","CEO Edward L. Rand, Jr. receives $998,400; CFO Dana S. Hendricks receives $369,873.","Other NEOs: Jeffrey P. Lisenby $381,998, Kevin M. Shook $348,098, Robert D. Francis $450,000.","Payments aim to mitigate potential 'excess parachute payments' under IRC Section 280G in connection with pending merger with The Doctors Company."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":117879,"accession_number":"0001127703-25-000012","cik":1127703,"company_name":"PROASSURANCE CORP","ticker":"PRA","form_type":"8-K","filed_at":"2025-11-04T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"ProAssurance Q3 net income $1.4M; merger with Doctors Co. pending regulatory approvals","event_type":"earnings","confidence":"high","bullets":["Q3 net income $1.4M ($0.03 diluted EPS); operating income $7.9M ($0.15 diluted EPS).","Consolidated net premiums written $261.3M; Specialty P&C renewal premiums up 8%.","Non-GAAP combined ratio 112.2% (consolidated), 109.1% (Specialty P&C).","Book value per share $25.37, up from $23.49 at year-end 2024.","Doctors Co. merger approved by 5 state regulators; pending in CA, PA, TX; closing expected by June 30, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":0.34,"consensus_revenue_estimate":null,"consensus_revenue_actual":828385000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":134334,"accession_number":"0002031090-25-000015","cik":1127703,"company_name":"PROASSURANCE CORP","ticker":"PRA","form_type":"8-K","filed_at":"2025-08-05T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"ProAssurance reports Q2 net income $21.9M ($0.42 EPS); merger with Doctors Co. on track","event_type":"earnings","confidence":"high","bullets":["Net income $21.9M ($0.42 diluted EPS); operating income $26.8M ($0.52 diluted EPS) for Q2 2025.","Specialty P&C net premiums written stable at $135.9M; renewal premium increases of 10% (cumulative >70% since 2018).","Non-GAAP combined ratio improved 9.5 ppts YoY; net investment income up 6%.","Book value per share $24.80, up $1.31 from year-end; adjusted book value $27.07.","Stockholders approved merger with The Doctors Company; FTC granted early termination; expected close H1 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":0.31,"consensus_revenue_estimate":null,"consensus_revenue_actual":548831000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":134333,"accession_number":"0002031090-25-000013","cik":1127703,"company_name":"PROASSURANCE CORP","ticker":"PRA","form_type":"8-K","filed_at":"2025-07-07T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"FTC grants early termination of HSR waiting period for ProAssurance acquisition by Doctors Company","event_type":"m_and_a","confidence":"high","bullets":["U.S. FTC granted early termination of HSR Act waiting period on July 2, 2025.","Merger of ProAssurance into The Doctors Company expected to close in first half of 2026.","Closing remains subject to other customary conditions and remaining regulatory approvals.","Both companies will operate independently until closing occurs."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.5,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":151147,"accession_number":"0002031090-25-000010","cik":1127703,"company_name":"PROASSURANCE CORP","ticker":"PRA","form_type":"8-K","filed_at":"2025-06-24T23:59:59+00:00","items":["5.07","8.01","9.01"],"status":"ready","headline":"ProAssurance shareholders approve acquisition by The Doctors Company with over 99% vote in favor","event_type":"m_and_a","confidence":"high","bullets":["Stockholders voted 38,225,337 for, 363,050 against, 22,192 abstain; over 99% of votes cast in favor.","Merger expected to close first half of 2026, pending regulatory approvals (HSR and state insurance).","Transaction is not subject to a financing condition.","Upon closing, ProAssurance will become wholly owned subsidiary of The Doctors Company; shares delisted from NYSE."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":151146,"accession_number":"0002031090-25-000007","cik":1127703,"company_name":"PROASSURANCE CORP","ticker":"PRA","form_type":"8-K","filed_at":"2025-05-21T23:59:59+00:00","items":["5.02","5.07"],"status":"ready","headline":"ProAssurance elects three directors, board reduced to nine; audit chair changed","event_type":"other_material","confidence":"high","bullets":["Stockholders elected DiPiazza, Frei, and Syphax to three-year terms at May 21, 2025 annual meeting.","Kedrick Adkins did not stand for re-election; board downsized from 10 to 9 directors.","Richard Bielen appointed Audit Committee chair, succeeding Adkins; DiPiazza also joins committee.","Ernst & Young LLP ratified as independent auditor for FY2025 with 44.5M votes for.","Advisory vote on 2024 executive compensation approved with 38.1M for, 2.1M against."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}